Motilal Oswal Financial Services maintains 'Buy' calls on seven stocks this week across metals, information technology services, cement, real estate, auto components, pharmaceuticals, and NBFC sectors. According to reports from The Financial Express, each recommendation rests on a different operating story and valuation argument. The brokerage's portfolio includes LTM Ltd. with a target price of ₹5,400 (35% upside), Hindalco Industries at ₹1,280 (15% upside), Dalmia Bharat at ₹2,230 (25% upside), Prestige Estates Projects at ₹1,680 (21% upside), Happy Forgings at ₹1,652 (20% upside), Sun Pharmaceutical Industries at ₹2,120 (15% upside), and Indostar Capital Finance with a target price of ₹290 (new recommendation).
Motilal Oswal maintains a 'Buy' rating on Hindalco Industries Ltd. with a target price of ₹1,280, implying an upside of 15%. As reported by The Financial Express, the brokerage reiterates its positive stance after a quarter that exceeded estimates across key operating metrics. Consolidated revenue stood at ₹78,130 crore in Q4 FY26, rising from ₹64,890 crore in the same quarter last year, representing 20% year-on-year growth and 18% quarter-on-quarter growth. Revenue came in 8% above Motilal Oswal's estimate. Adjusted profit after tax stood at ₹5,800 crore against the estimate of ₹4,200 crore, while earnings before interest, taxes, depreciation and amortisation stood at ₹10,020 crore against the brokerage estimate of ₹8,640 crore. Novelis also delivered ahead of expectations with adjusted earnings before interest, taxes, depreciation and amortisation at $459 million against Motilal Oswal's estimate of $380 million, despite a $54 million shipment impact and $577 million cash flow loss related to the Oswego fire. The facility is expected to restart in June 2026, with volume and earnings recovery beginning in the second or third quarter of FY27.
Motilal Oswal maintains a 'Buy' rating on LTM Ltd. with a target price of ₹5,400, implying an upside of 35%. According to The Financial Express, the brokerage retains its recommendation after the company announced the acquisition of Randstad's technology services business across Europe and Australia. The acquired business generates annual revenue of around €469 million and employs nearly 2,900 billable professionals. LTM is acquiring the asset for about €160 million, implying roughly 0.3 times enterprise value to sales. The transaction also includes a five year global capability centre and artificial intelligence transformation agreement for Randstad's India operations with total contract value estimated at €50 million to €60 million. After completion, LTM's European revenue is expected to cross $1 billion while Australian revenue is expected to move above $100 million. Motilal Oswal projects adjusted earnings per share at ₹213 in FY27 and ₹235.5 in FY28, and notes the acquisition is likely to remain earnings per share neutral and consume only 10% to 15% of available cash.
Motilal Oswal maintains a 'Buy' rating on Dalmia Bharat with a target price of ₹2,230, implying an upside of 25%. As reported by The Financial Express, the brokerage continues to back the stock after Dalmia Bharat announced the acquisition of Jaiprakash Associates' cement assets in Central India. The transaction includes 3.3 million tonnes per annum of clinker capacity, 2.5 million tonnes per annum of grinding capacity, a 99 megawatt thermal plant and railway infrastructure. Enterprise value stands at ₹2,850 crore or roughly $57 per tonne. Total installed capacity is expected to increase to 54.7 million tonnes per annum from 49.5 million tonnes per annum immediately after completion. Expansion projects in Belgaum, Pune and Kadapa are expected to take capacity to 66.7 million tonnes per annum by the third quarter of FY28. Motilal Oswal expects the acquisition to add around 3% to FY27 earnings estimates and 7% to FY28 estimates, noting the transaction strengthens Dalmia Bharat's positioning in Central India where pricing remains stronger than southern markets.
Motilal Oswal maintains a 'Buy' rating on Prestige Estates Projects Ltd. with a target price of ₹1,680, implying an upside of 21%. According to The Financial Express, the brokerage retains its positive view after Prestige Estates reported one of its strongest annual pre-sales performances. Pre-sales reached ₹30,000 crore in FY26, increasing from ₹17,000 crore in FY25, a rise of 76% year-on-year. Around 63% came from new launches. Gross development value launched during the year stood at ₹27,400 crore. Bengaluru contributed 34% of bookings and the National Capital Region accounted for 33%, while Mumbai contributed 20% and other markets contributed 13%. TPC Indirapuram generated ₹9,600 crore in pre sales, Prestige Nautilus contributed ₹3,000 crore and Prestige Southern Star Phase 1 generated ₹2,100 crore. Collections increased to ₹18,500 crore from ₹12,100 crore in FY25, while operating cash flow rose to about ₹7,000 crore from around ₹4,500 crore. The company guides for 15% to 20% pre-sales growth in FY27.
Motilal Oswal maintains a 'Buy' rating on Happy Forgings Ltd. with a target price of ₹1,652, implying an upside of 20%. As reported by The Financial Express, the brokerage raises earnings estimates after the company reported results ahead of expectations. Standalone profit after tax stood at ₹83.6 crore in Q4 FY26 against Motilal Oswal's estimate of ₹79.7 crore. Revenue increased to ₹420 crore from ₹349 crore in the year ago quarter, a growth of 20.4%. Earnings margin expanded by 240 basis points to 31.5%. Shipments reached 17,298 metric tonnes while realisation remained stable at ₹245 per kilogram. The company reported an order book of ₹950 crore to be executed over the next two to three years, with around ₹250 crore from heavy forgings linked to data centre applications. Average realisation on the new order book stands at ₹345 to ₹350 per kilogram. Management guides for late teens volume growth in FY27 and implemented a 3.5% to 4% price increase across most original equipment manufacturer customers.
Motilal Oswal has issued a 'Buy' rating on Indostar Capital Finance with a target price of ₹290, marking a new addition to their portfolio. As reported by Moneycontrol, the brokerage's research report dated May 28, 2026, highlights that elevated SR provisions led to reported losses during the quarter, but provisioning is now complete. The company reported a mixed operating performance with pickup in business momentum as evident in sequential improvement in both disbursements and AUM growth. However, asset quality weakened during the quarter as GS3 rose ~70bp QoQ due to slippage from the legacy loan book. Despite the quarterly challenges, Motilal Oswal estimates a CAGR of 24%/62% in AUM/PAT over FY26-28, aided by expansions in NIM to 9.9%/9.8% in FY27E/FY28E, moderation in credit costs, and improvement in operating efficiencies. The target price of ₹290 is premised on 1.1x Mar'28E BVPS.
Motilal Oswal maintains a 'Buy' rating on Sun Pharmaceutical Industries Ltd. with a target price of ₹2,120, implying an upside of 15%. According to The Financial Express, the brokerage retains its recommendation despite reducing earnings estimates for FY27 and FY28. Revenue increased to ₹14,560 crore in the fourth quarter of FY26 from ₹12,816 crore in the same quarter last year, a growth of 13.6%. Gross margin improved to 80.8%. Earnings margin narrowed to 23.9% due to higher marketing spending and lower milestone income. Adjusted profit after tax stood at ₹2,387 crore against the brokerage estimate of ₹2,970 crore. Innovative medicines grew 20% year on year in the quarter and accounted for 22% of total sales. Illumya generated $797 million in FY26 revenue, rising from the previous year by 16.7%. The United States Food and Drug Administration accepted the filing for psoriatic arthritis with an action date in October 2026. Domestic formulations revenue increased to ₹4,836 crore from ₹4,213 crore, while emerging markets revenue rose to ₹2,800 crore from ₹2,182 crore. Management guides for high single digit revenue growth in FY27 and research spending of 6% to 7% of sales.
